Agerbaek M, Gerdes L U, Richelsen B
Medical Department A, Aarhus University Hospital, Denmark.
Eur J Clin Nutr. 1995 May;49(5):346-52.
There are still controversies as to the potential beneficial effects of milk and fermented milk products on the level of lipoproteins. The objective of the present investigation was to test the effect of a moderate daily intake of a new fermented milk product, which was based on a bacterial culture obtained from the intestinal flora of inhabitants of Abkhasia, on the lipoprotein levels of a homogeneous group of middle-aged Danish men.
The study was randomised, double-blind, and placebo-controlled, and the intervention was performed for a period of 6 weeks.
Fifty-eight healthy, non-obese, normocholesterolaemic, male volunteers born in 1949 of Danish descent participated (i.e. all were 44 years old).
During the intervention period the subjects' habitual diets were supplemented with 200 ml/day of either the new fermented milk product or a placebo product (chemically fermented). The biologically fermented milk product contained Enterococcus faecium and two strains of Streptococcus termophilus. Fasting blood samples were drawn initially and after 3 and 6 weeks and analysed for plasma values of total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglyceride. In addition, LDL-cholesterol was estimated.
After these 6 weeks total cholesterol was reduced significantly in the group given biologically fermented milk (-0.37 mmol/l, confidence interval: -0.51 to -0.23) while no changes were observed in the placebo group (-0.02 mmol/l) (P < 0.01). This reduction in total cholesterol could be completely ascribed to a fall in LDL-cholesterol by 10% (i.e. -0.42 mmol/l) since HDL-cholesterol and triglyceride were unchanged in both groups.
Thus, this short-term study (6 weeks) demonstrated an LDL-cholesterol-lowering effect (10% reduction) of a new fermented milk product in middle-aged Danish men.
关于牛奶和发酵奶制品对脂蛋白水平的潜在有益作用仍存在争议。本研究的目的是测试每日适量摄入一种新型发酵奶制品对一组同质的中年丹麦男性脂蛋白水平的影响,该发酵奶制品基于从阿布哈兹居民肠道菌群中获得的一种细菌培养物。
该研究为随机、双盲、安慰剂对照试验,干预为期6周。
58名健康、非肥胖、血胆固醇正常的丹麦裔男性志愿者参与研究(均为1949年出生,即年龄均为44岁)。
在干预期间,受试者的日常饮食中每天补充200毫升新型发酵奶制品或安慰剂产品(化学发酵)。生物发酵奶制品含有粪肠球菌和两株嗜热链球菌。在研究开始时、3周后和6周后采集空腹血样,分析血浆总胆固醇、高密度脂蛋白(HDL)胆固醇和甘油三酯水平。此外,还估算了低密度脂蛋白(LDL)胆固醇水平。
6周后,食用生物发酵奶制品的组总胆固醇显著降低(-0.37毫摩尔/升,置信区间:-0.51至-0.23),而安慰剂组未观察到变化(-0.02毫摩尔/升)(P<0.01)。总胆固醇的降低完全归因于LDL胆固醇下降了10%(即-0.42毫摩尔/升),因为两组的HDL胆固醇和甘油三酯均未改变。
因此,这项短期研究(6周)表明,一种新型发酵奶制品对中年丹麦男性具有降低LDL胆固醇的作用(降低10%)。